AMENDMENT TO EQUITY PURCHASE AGREEMENTEquity Purchase Agreement • February 1st, 2021 • Adial Pharmaceuticals, Inc. • Pharmaceutical preparations
This AMENDMENT (the “Amendment”) is made and entered into as of the 25th day of January, 2021, to the EQUITY PURCHASE AGREEMENT, dated December 7, 2020 (the “Agreement”), by and among Adial Pharmaceuticals, Inc., a Delaware corporation (the “Purchaser”), Purnovate, Inc., a Delaware corporation and wholly owned subsidiary of Purchaser (“Merger Sub”), PNV Conversion Corp., a Virginia corporation, as successor-in-interest to Purnovate, LLC, a Virginia limited liability company (the “Company”), each of the members of the Company (collectively, the “Members”) and Robert D. Thompson, as representative of the Members (the “Members’ Representative”). Capitalized terms used and not defined herein shall have the meanings ascribed to them in the Agreement.
